Equities
  • Price (USD)26.51
  • Today's Change1.17 / 4.62%
  • Shares traded35.21k
  • 1 Year change+557.82%
  • Beta0.6577
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

  • Revenue in USD (TTM)-16.64m
  • Net income in USD-61.20m
  • Incorporated2003
  • Employees103.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inhibrx Biosciences Inc1.40m-155.09m1.10bn156.00------787.44-10.02-10.020.0905--0.007--4.968,974.36-77.54114.91-96.94138.28-----11,077.574,710.68---199.520.7307---88.89-56.75799.19--7.49--
Compass Therapeutics Inc.0.00-65.81m1.12bn35.00--5.32-----0.4577-0.45770.001.180.00----0.00-34.60-37.49-36.20-40.90-------28,561.77----0.00-------16.19---37.62--
MoonLake Immunotherapeutics0.00-210.50m1.13bn100.00--3.48-----3.33-3.330.004.540.00----0.00-45.83---50.02-------------43.630.2021-------230.31------
Savara Inc0.00-115.65m1.14bn59.00--10.26-----0.535-0.5350.000.54610.00----0.00-60.91-36.72-66.05-39.40-------109,477.80----0.2399-------75.29---29.93--
Nanobiotix SA - ADR-16.64m-61.20m1.22bn103.00---------1.29-1.29-0.351-1.69-0.213-----154,094.20-78.34-54.39-839.67-90.60-------1,326.20---7.32-----138.62---71.62---10.10--
Septerna Inc22.05m-58.81m1.23bn75.00--3.16--55.85-1.51-1.510.53048.710.0565--4.98293,933.30-15.06---16.99-------266.77------0.00--611.92---12,762.79------
Taysha Gene Therapies Inc6.31m-99.93m1.25bn73.00--5.69--197.52-0.3328-0.33280.02120.79950.0254----86,438.36-40.23-70.59-45.55-88.39-----1,583.66-2,287.96----0.1899---46.07--19.96------
AtaiBeckley Inc3.02m-154.19m1.30bn54.00--5.37--428.91-0.8136-0.81360.01610.66440.0138--0.335455,981.48-70.56-45.69-77.07-50.03-----5,104.20-2,658.81----0.00---1.91---271.09--37.97--
Monte Rosa Therapeutics Inc181.54m20.95m1.31bn147.0071.524.5044.637.200.25060.25062.203.980.4685--65.301,354,761.005.41-33.146.24-39.19----11.54-563.84----0.00------46.29--23.56--
Azenta Inc594.95m28.69m1.32bn3.00k45.770.76815.432.220.6252-1.2612.9837.260.28914.034.00198,317.701.39-0.39011.57-0.432844.5945.324.82-1.732.61--0.00--3.558.85200.38---3.24--
Rapport Therapeutics Inc0.00-97.70m1.33bn69.00--2.60-----2.71-2.710.0010.740.00----0.00-22.55---23.12--------------0.00-------125.11------
Trevi Therapeutics Inc0.00-45.86m1.33bn26.00--7.03-----0.3713-0.37130.001.480.00----0.00-34.19-45.07-36.67-51.11------------0.00-------64.84--31.21--
Kodiak Sciences Inc0.00-217.34m1.35bn123.00--49.37-----4.12-4.120.000.4470.00----0.00-73.58-33.79-82.91-35.95------------0.00------32.36---1.75--
Data as of Feb 17 2026. Currency figures normalised to Nanobiotix SA's reporting currency: US Dollar USD

Institutional shareholders

0.09%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. International Plcas of 31 Dec 202522.92k0.05%
Marshall Wace LLPas of 31 Dec 20259.50k0.02%
Optiver US LLCas of 30 Sep 20255.36k0.01%
BNP Paribas Financial Marketsas of 31 Dec 20253.60k0.01%
RhumbLine Advisers LPas of 31 Dec 20252.34k0.01%
UBS Securities LLCas of 31 Dec 20251.53k0.00%
EverSource Wealth Advisors LLCas of 31 Dec 2025514.000.00%
GAMMA Investing LLCas of 31 Dec 2025229.000.00%
Wells Fargo Clearing Services LLCas of 31 Dec 2025200.000.00%
RBC Capital Markets LLC (Investment Management)as of 30 Sep 2025125.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.